D
David Gruben
Researcher at Pfizer
Publications - 86
Citations - 6422
David Gruben is an academic researcher from Pfizer. The author has contributed to research in topics: Tofacitinib & Janus kinase inhibitor. The author has an hindex of 24, co-authored 73 publications receiving 5492 citations.
Papers
More filters
Journal ArticleDOI
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Roy Fleischmann,Joel M. Kremer,John J. Cush,Hendrik Schulze-Koops,Carol A. Connell,John D. Bradley,David Gruben,Gene V. Wallenstein,Samuel H. Zwillich,Keith S. Kanik +9 more
TL;DR: In patients with active rheumatoid arthritis, tofacitinib monotherapy was associated with reductions in signs and symptoms of rheumatism and improvement in physical function and tofacit inib treatment wasassociated with elevations in low-density lipoprotein cholesterol levels and reductions in neutrophil counts.
Journal ArticleDOI
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis
Ronald F van Vollenhoven,Roy Fleischmann,Stanley Cohen,Eun Bong Lee,Juan A. García Meijide,Sylke Wagner,Šárka Forejtová,Samuel H. Zwillich,David Gruben,Tamas Koncz,Gene V. Wallenstein,Sriram Krishnaswami,John D. Bradley,Bethanie Wilkinson +13 more
TL;DR: In patients with rheumatoid arthritis receiving background methotrexate, tofacitinib was significantly superior to placebo and was numerically similar to adalimumab in efficacy.
Journal ArticleDOI
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
Gerd R Burmester,Ricardo Blanco,Christina Charles-Schoeman,Jürgen Wollenhaupt,Cristiano A. F. Zerbini,B. Benda,David Gruben,Gene V. Wallenstein,Sriram Krishnaswami,Samuel H. Zwillich,Tamas Koncz,Koshika Soma,John S. Bradley,Charles A Mebus +13 more
TL;DR: In this treatment-refractory population, tofacitinib with methotrexate had rapid and clinically meaningful improvements in signs and symptoms of rheumatoid arthritis and physical function over 6 months with manageable safety.
Journal ArticleDOI
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
E.B. Lee,Roy Fleischmann,Stephen Hall,Bethanie Wilkinson,John D. Bradley,David Gruben,Tamas Koncz,Sriram Krishnaswami,Gene V. Wallenstein,Chuanbo Zang,Samuel H. Zwillich,Ronald F van Vollenhoven +11 more
TL;DR: Tofacitinib monotherapy was superior to methotrexate in reducing signs and symptoms of rheumatoid arthritis and inhibiting the progression of structural joint damage.
Journal ArticleDOI
The Safety and Efficacy of a JAK Inhibitor in Patients With Active Rheumatoid Arthritis Results of a Double-Blind, Placebo-Controlled Phase IIa Trial of Three Dosage Levels of CP-690,550 Versus Placebo
Joel M. Kremer,Bradley J. Bloom,Ferdinand C. Breedveld,John Coombs,Mark P. Fletcher,David Gruben,Sriram Krishnaswami,Ruben Burgos-Vargas,Bethanie Wilkinson,Cristiano A. F. Zerbini,Samuel H. Zwillich +10 more
TL;DR: It is indicated that CP-690,550 is efficacious in the treatment of RA, resulting in rapid, statistically significant, and clinically meaningful reductions in the signs and symptoms of RA.